Survodutide

Summary

Survodutide is an investigational once-weekly injectable that hits two receptors at once: glucagon and GLP-1. That combination is the point. GLP-1 activation suppresses appetite — the mechanism behind semaglutide — while glucagon-receptor activation is thought to increase energy expenditure and act directly on the liver. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon instead, making it a genuinely different bet rather than another GLP-1 variant. The published human evidence is a 387-person Phase 2 trial in which the highest dose produced 14.9% average weight loss over 46 weeks against 2.8% on placebo. That is a real, well-controlled result, but it is Phase 2: the Phase 3 programme is running and its efficacy results were not published at the time of writing. It is not approved anywhere.

What people use it for

Weight loss, primarily, and type 2 diabetes, where a separate Phase 2 trial measured blood-sugar and weight response. A third line of research targets MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), where the glucagon component's direct liver effects are the rationale — a Phase 2 trial in patients with fibrosis is registered. Because survodutide is trial-only, there is no prescribing population; interest outside trials is driven by the obesity-drug pipeline conversation and by gray-market material sold under the name.

Human evidence

The Phase 2 obesity trial (the substantive evidence). Published in Lancet Diabetes & Endocrinology in 2024, this randomized, double-blind, placebo-controlled dose-finding trial enrolled 387 adults aged 18–75 with a BMI of 27 or above and without diabetes, giving once-weekly subcutaneous survodutide or placebo for 46 weeks. Mean body-weight change was clearly dose-dependent:

A clean dose-response curve across nearly 400 randomized participants is good evidence that the effect is real. It is still a single Phase 2 trial, which is why the weight-loss claim grades S rather than S+ — the bar for S+ on this site is multiple large trials or an approved, settled evidence base, and survodutide has neither yet.

Type 2 diabetes. A separate randomized trial examined dose-response for HbA1c and body weight against both placebo and open-label semaglutide. It supports a real glucose-lowering effect, and again it is Phase 2 evidence in one population, so this claim also grades S.

What has not been shown. There is no published head-to-head trial establishing that survodutide beats semaglutide or tirzepatide on weight loss. The 14.9% figure came at 46 weeks, while semaglutide's pivotal result was measured at 68 weeks and tirzepatide's at 72 — different trials, different durations, different populations, so the numbers are not directly comparable. Anyone presenting survodutide as the strongest of the class is comparing across trials that were never designed to be compared, which is why that claim grades C. Phase 3 (SYNCHRONIZE-1 and -2) and a cardiovascular-outcomes trial are running; baseline-characteristics papers have appeared, but the efficacy results had not been published when this brief was written.

Animal / preclinical evidence

The dual-agonist rationale is well grounded. Glucagon-receptor agonism raises energy expenditure and drives hepatic fat oxidation, while GLP-1 agonism reduces food intake and offsets glucagon's tendency to raise blood glucose — the pairing is designed so each partner covers the other's weakness. Preclinical work in this class established that balance, and it explains why the MASH programme exists: a drug acting directly on liver fat metabolism is a plausible candidate there. As with cagrilintide, the human data is now the stronger evidence, so the grades above rest on the trials rather than the animal work.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Survodutide is available only through trials, so there is no legitimate user community. Discussion online concerns material bought from research-chemical suppliers under this name, which cannot be assumed to be the trial compound, to contain what the label claims, or to be sterile. Reports of appetite suppression and nausea match the pharmacology, but they describe an unverified substance and carry no evidentiary weight.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The Phase 2 trial tested 0.6, 2.4, 3.6 and 4.8 mg once weekly by subcutaneous injection over 46 weeks, with escalation to the assigned target. The ongoing Phase 3 SYNCHRONIZE-1 trial up-titrates to 3.6 mg or 6.0 mg once weekly over 76 weeks. These describe what was administered to enrolled participants under clinical supervision with a known product and monitoring. They are not a protocol, and they do not transfer to material of unverified identity bought outside a trial.

Safety & side effects

In the Phase 2 trial, adverse events occurred in 91% of survodutide recipients (281 of 309) against 75% on placebo (58 of 77), and were primarily gastrointestinal — 75% versus 42%. That is a high rate, though a dose-finding trial deliberately pushes doses toward the tolerability ceiling, and gastrointestinal effects are the class signature for GLP-1-based drugs. The glucagon component adds questions a GLP-1 alone does not, including effects on heart rate and glucose, which is part of why a dedicated cardiovascular-outcomes trial is running. Long-term safety is genuinely unknown: no Phase 3 safety dataset has been published. And none of this addresses unregulated product, where the risks of unknown identity, purity and sterility sit on top of the drug's own profile.

Regulatory / legal status

Survodutide is investigational and not approved anywhere — not by the FDA, the EMA, or any other major regulator — and is not available by prescription. Legitimate access is through clinical trials only. Development is by Boehringer Ingelheim with Zealand Pharma, under the code BI 456906. The Phase 3 obesity programme (SYNCHRONIZE-1 and -2) and a cardiovascular-outcomes trial are ongoing. Anything sold online as "survodutide" is not the trial drug, has been through no regulatory review, and its contents are unverified — which is why that claim grades C. Status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

Survodutide appears in obesity-drug coverage as one of the next-generation candidates, usually alongside retatrutide and CagriSema, and often framed as potentially stronger than what is on the market. The Phase 2 result behind that framing is real and well conducted. What the framing omits is that the comparison is indirect: the 14.9% figure comes from a 46-week Phase 2 trial, and setting it beside semaglutide's or tirzepatide's numbers from longer, larger, separately designed trials does not establish which is stronger. The Phase 3 results that could settle it had not been published when this brief was written.